

Chlorhexidine Gluconate (CHG) Solution Market Poised for Steady Growth Driven by Rising Antiseptic Needs

chlorohexidine gluconate solution market size was USD 181.3 Million in 2022 and is expected to register a revenue CAGR of 1.90% during the forecast period

VANCOUVER, BRITISH COLUMBIA, CANADA, June 19, 2024
/EINPresswire.com/ -- The
Chlorhexidine Gluconate (CHG)
solution market is anticipated to witness consistent growth over the coming years, driven by a surge in demand for effective antiseptic solutions across various applications.



According to Emergen Research, the market size is expected to reach \$219.63 Million by 2032, reflecting a CAGR of 38.6% during the forecast period 2022-2032

Market Overview

CHG solution is a widely used antiseptic agent known for its broad-spectrum antimicrobial activity. It is primarily used in healthcare settings for skin disinfection, surgical site preparation, and hand hygiene. The rising prevalence of healthcare-associated infections (HAIs) and increasing awareness of infection control measures are key factors propelling the CHG solution market forward.

You Can Download Free Sample PDF Copy Of This Report@ https://www.emergenresearch.com/request-sample/2532

Market Trends

Several trends are shaping the CHG solution market landscape:

Growing demand for hand rubs: The hand rub segment holds the dominant position within the

market, driven by the rising focus on hand hygiene to prevent the spread of infections, particularly in the wake of the COVID-19 pandemic.

Focus on environment-friendly formulations: Manufacturers are increasingly developing CHG solutions with eco-friendly ingredients to address environmental concerns associated with traditional formulations.

Rise of telemedicine and remote care: The growing adoption of telemedicine and remote care solutions is expected to influence the demand for CHG wipes for at-home wound care and disinfection.

Market Drivers

Increasing surgical procedures: The growing number of surgical procedures globally necessitates the use of CHG solutions for pre-operative skin preparation, thereby driving market expansion.

Aging population: The burgeoning elderly population, more susceptible to infections, is expected to fuel the demand for CHG solutions in healthcare facilities.

Government initiatives for infection control: Stringent government regulations and growing emphasis on healthcare hygiene protocols are promoting the use of CHG solutions.

Market Restraints

Potential skin irritation: CHG solutions can cause skin irritation with prolonged use, particularly in individuals with sensitive skin, which may limit market growth.

Emerging resistance: The emergence of resistance to CHG among certain bacterial strains is a potential concern that needs to be addressed by the market.

Growth Opportunities


Development of novel formulations: The introduction of CHG solutions with improved efficacy, longer-lasting activity, and reduced skin irritation presents significant growth opportunities.

Expansion into emerging markets: Increasing healthcare spending and growing awareness of hygiene practices in developing countries offer lucrative avenues for market expansion.

Focus on home healthcare: The rising popularity of home healthcare services is expected to create demand for CHG solutions for use in domestic settings.

Find More Competitor in TOC with Profile Overview Share Growth Analysis

@ https://www.emergenresearch.com/industry-report/chlorhexidine-gluconate-solution-market



Xttrium Laboratories.

Afton Pharma
MEDICHEM S.A.
3M
BD
Ecolab
Lupin
Sage Products LLC
Clinicept Healthcare Ltd.
Coloplast Corp
Convatec Group PLC
Cardinal Health.
GAMA Healthcare Ltd
Medline Industries, Inc.
Latest Developments
On 3 April 2023, 3M Health Care today announced the introduction of its new Food and Drug Administration (FDA)-approved 3M SoluPrep S Sterile Antiseptic Solution chlorhexidine gluconate (2% w/v) and isopropyl alcohol (70% v/v) Patient Preoperative Skin Preparation. The product has been shown to provide fast-acting, broad-spectrum antimicrobial activity (in vitro, clinical significance unknown) and persistence in healthy human volunteers for at least 96 hours post-prep.

On 26 September, Cosmos Health company a diversified, vertically integrated global healthcare group engaged in innovative Research and Development (R&D), owner of proprietary nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced the expansion of its C-Sept brand with the launch of the new C-Scrub Wash 4% CHG Biocide.

Request For Customization: https://www.emergenresearch.com/request-for-customization/2532

Chlorhexidine Gluconate (CHG) Solution Market Segment Analysis

For the purpose of this report, Emergen Research has segmented the global chlorhexidine gluconate solution market on the basis of product type, application, distribution channel, and region:

Product Type Outlook (Revenue, Volume, USD Million, Kilotonnes; 2019-2032)

2% Chlorhexidine Gluconate Solution

4% Chlorhexidine Gluconate Solution

20% Chlorhexidine Gluconate Solution

Application Outlook (Revenue, Volume, USD Million, Kilotonnes; 2019-2032)

Preoperative Skin Preparation

Surgical Hand Rub

Skin Wound and General Skin Cleanser

Healthcare Personal Hand Hygiene

Distribution Channel Outlook (Revenue, Volume, USD Million, Kilotonnes; 2019-2032)

Online

Offline

Eric Lee
Emergen Research
+91 90210 91709
sales@emergenresearch.com
Visit us on social media:
Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/721305232 EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something

we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.